Project description
Tumour hypoxia: friend or foe?
Low availability and uneven distribution of oxygen in the tumour microenvironment creates regions of hypoxia. Hypoxic conditions can promote cancer cell survival, genetic instability, and resistance to apoptosis, hampering the effectiveness of various treatments at the same time. Funded by the European Innovation Council, the TUMAGNOSTIC project aims to exploit hypoxia as a therapeutic target and promote a hypoxia-activated prodrug (HAP) called CP-506 for cancer treatment. This new approach integrates AI-driven biomarkers to increase the effectiveness of HAPs and improve clinical outcomes. Importantly, it can be used in conjunction with other types of therapies such as immunotherapy for improved efficacy.
Objective
TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours. CP-506 overcomes the limitations of previous HAP development attempts and can provide more targeted treatment compared with alternatives such as chemo-immunotherapy combination and PARPi. Our approach, combining CP-506 with improved patient targeting based on two AI-driven biomarkers (tumour hypoxia and Homologous Recombination Defect), has high potential to increase the effectiveness of standard of care therapies such as immunotherapy (IO) in combination therapy (prodrug-IO) and improve patients progression free survival and quality of life in several cancer types. We aim to advance CP-506 towards commercialization by carrying out a phase I-IIa clinical trial and corresponding business development activities, paving the way for a licensing agreement with the potential to exceed 450M.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
4000 Liege
Belgium
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.